Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 5/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902015 | 0.84 | RAB9A (0.33) | RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4260867 | 0.83 | RAB9A (0.50) | RAB9AMAPTNPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12200566 | 0.80 | MAPK1 (0.40) | MAPK1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2902595 | 0.79 | RAB9A (0.30) | RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL8881208 | 0.77 | — | — | |
| SCHEMBL973531 | 0.71 | — | — | |
| SCHEMBL12200521 | 0.70 | IRAK4 (0.31) | — | |
| SCHEMBL12200518 | 0.70 | IRAK4 (0.31) | — | |
| SCHEMBL20323169 | 0.67 | MAPK1 (0.40) | MAPK1RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21176463 | 0.67 | ALDH1A1 (0.32) | ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2116535-B1 | GLUCOKINASE-ACTIVATING SUBSTANCE | KYORIN SEIYAKU KK (JP) | 2014-06-11 | — | — | EP | disclosed |
| EP-2116533-B1 | GLUCOKINASE ACTIVATOR | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8173649-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173649-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2116535-A1 | GLUCOKINASE-ACTIVATING SUBSTANCE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009133687-A1 | CYCLOPENTYLACRYLIC ACID AMIDE DERIVATIVE | 杏林製薬株式会社 (JP) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | MAPK1 140/4885RAB9A 1897/4885MAPT 4692/4885 |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | MAPK1 929/4885RAB9A 2029/4885MAPT 4834/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | MAPK1 929/4885RAB9A 2029/4885MAPT 4834/4885 |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | MAPK1 219/4885RAB9A 2252/4885MAPT 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.